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OBJECTIVES: To estimate the clinical and economic impact of saxagliptin (SAXA)
versus sulfonylurea (SU), both with metformin (MET), on the reduction of hypogly-
cemia among individuals with type 2 diabetes (T2D) in clinical practice.METHODS:
Our analysis combined data from several sources to estimate outcomes on a per-
patient and health plan-population level. Patient survey data (n91) were used to
estimate real-world rates of hypoglycemia for patients treated with SUMET,
while the relative risk reduction observed in the pivotal SAXA clinical trial was
applied to estimate the proportion of patients receiving SAXAMET who experi-
ence1 hypoglycemia event. Costs associated with hypoglycemia treatment were
obtained from an administrative claims analysis (n813) and epidemiologic data
were obtained from the literature. Costs are reported in 2011 USD. RESULTS: Treat-
ment with SAXAMETwas estimated to reduce the probability of experiencing1
event from 68.1% to. 5.6% (net -62.5%). At these rates, resultant annual costs when
all diabetes-related medical claims were considered were $435/patient treated
with SUMET and $36/patient treated with SAXAMET, an annual cost savings of
$399/patient receiving SAXAMET. If 50% of eligible patients in a 100,000-member
health plan were switched from SUMET to SAXAMET, the net diabetes-related
cost savings due to reduced hypoglycemia was estimated at $216,000 in 2011,
increasing to $230,000 by 2013 (net savings of $0.19 per-member-per-month).
When only confirmed events [i.e., symptom(s)  blood glucose 70mg/dL] were
considered, the net reduction in event rate was -24.2%, with annual cost savings
predicted at $209/patient or $113,000-121,000 on a health plan level (savings of
$0.10 per-member-per-month). CONCLUSIONS: When clinical trial results for
SAXAMET are translated to actual clinical practice, the model predicts the lower
rate of hypoglycemia (considering all events as well as confirmed events only)
relative to treatment with SUMETwill result in considerable cost savings on both
a per-patient and health-plan level.
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OBJECTIVES: Hypoglycemic events are a common complication associated with
diabetes and the majority of these events are mild and self treated by the patient.
For severe hypoglycemic events, however, hospital visits are often required. This
study was conducted to better understand the impact of medical attendance re-
quired to care for severe hypoglycemic events on total annual health care costs.
METHODS: A 1:1 matched case-control cohort analysis was conducted in the US
using the IMS LifeLink™ Health Plan Claims Database. Patients were included as
cases if they experienced at least one hypoglycemic event in 2009 which required
hospitalization and as controls if they did not experience any hypoglycemic event.
Cases and controls were matched by age, gender, type of diabetes, baseline co-
morbidities and payer type. Univariate and multiple regression analyses on total
annual health care costs were conducted. RESULTS: A total of 1878 matched cases
and controls were included. The mean age was 58.6 (13.7) years old, 51.2% of pa-
tients were males and 97.2% of patients had type II diabetes. Patients were mostly
covered by commercial health insurance (69%) and Medicare (20.1%). The mean
baseline Charlson Co-morbidity Index was 3.5 (2.5), and the main baseline co-
morbidities were hypertension (77.0%) and dyslipidemia (48.4%). Univariate results
showed that cases with severe hypoglycemic events had significantly higher total
annual healthcare costs than their respective controls ($32,337 vs. $19,786,
p-value0.0001). These results were confirmed by themultivariate analyses which
showed that severe hypoglycemic events led to a statistically significant 1.66-fold
(95%CI  [1.35; 2.04]) increase of total annual health care costs compared to con-
trols, after adjusting for other relevant co-factors such as region and
co-morbidities.CONCLUSIONS:Themedical attendance required to care for severe
hypoglycemic events in patients with diabetes was found to have a significant
impact on total annual health care costs.
PDB38
OBESITY AND WEIGHT CHANGE EFFECTS ON HEALTH CARE COSTS OF
DIABETES: A SYSTEMATIC REVIEW STUDY
Sharifi A, Farshchi A, Naghavi M, Esteghamati A
Tehran University of Medical Sciences, Tehran, Iran
OBJECTIVES:Diabetes is a serious, costlymetabolic disorder. The economic burden
of obesity has been described in many studies. This review aims to provide an
update on excess health care costs of diabetes attributed to overweight and obesity.
METHODS: This review is based on a PubMed search of the English language liter-
atures published until November 30, 2011. Search conducted by keywords of “Cost”,
“Obesity” and “Diabetes”with Title/Abstract limitation. This searchwas completed
by reviewing the reference section of each article obtained to check other surveys
not included in the database. RESULTS: A total of 479 articles were cited, 27of
whichmet the inclusion criteria. Of these 27 studies, 11 concluded that obesity can
cause incremental medical costs of diabetes. Seven studies assessed the effect of
weight change on diabetes costs, among which; five studies showed that decreas-
ing in medical costs of diabetes can be a consequence of weight reduction and the
other two studies provided estimation of incremental costs of diabetes that is
attributed to weight gain. Eight studies examined costs of diabetes to be attributed
to obesity or overweight. According to the result of the only study left, obesity
decreases costs of diabetes. CONCLUSIONS: Obesity is a worldwide growing prob-
lem. Many literatures indicated that obesity accounts as an important risk factor
for many chronic diseases such as diabetes. The economic burden of obesity on
health care system iswell-known and its concomitancywith diabetes is associated
with incremental health care costs. This study suggests an urgent need to develop
new and effective interventions to control obesity and decrease its prevalence.
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OBJECTIVES: Diabetic patients often have other complications whose impacts on
health care costs are not always fully realized. The objective of this study was to
quantify these additional costs.METHODS: A 1:1 matched case-control 2-year fol-
low-up analysis was conducted using the IMS LifeLink™ Health Plan Claims Data-
base. Six cohorts were analysed: renal disorders (RD), heart disorders (HD), lower
limb disorders (LD), eye disorders (ED), hypoglycemia (HY) and neuropathy (NE).
Inclusion criteria included adult patients, a diabetes diagnosis in 2008, continuous
enrolment, no complication of interest (COI) during the pre-index period (all pa-
tients) and the post-index period (control patients). Patients were matched by age,
gender, type of diabetes, comorbidities, pre-index complications, payer and index
date. Results reported were demographics, other complications and healthcare
costs. A Gamma multiple regression model with a log-link determined the impact
of the COI on total annual healthcare costs, adjusted for other relevant co-factors.
RESULTS: The demographics across all cohorts were consistent with amean age of
52-55 years old, 53% of males, more than 99% of patients with type II diabetes and
more than 93% patients with commercial insurance. Total first year health care
costs in the HD, NE, RD, LD, and HY cohorts were statistically higher in cases with
a total cost increase varying from 20% (HY) to 152% (HD). Second year total health
care costs were statistically higher for cases in the HD and NE cohorts only with an
increase of 36% and 20% respectively compared to controls. The ED cohort did not
show any significant difference in health care costs between cases and controls.
CONCLUSIONS: Most diabetes COI were associated with significantly higher total
health care costs in the first year following the COI, with the exception of ED. This
association only remained significant during the second year for HD and NE.
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OBJECTIVES: To estimate direct and indirect costs associated with type 2 diabetes
(T2DM) in Tianjin, China. METHODS: Data were obtained from a cross-sectional
survey of patients with T2DM from October to December, 2011 in Tianjin, China.
Patients were eligible for the survey if theywere18 years, had T2DMdiagnosis for
1 year, and received antidiabetic treatment 1 year. T2DM-related outpatient
utilization and costs and direct non-medical costs were reported for the past 2
weeks and were extrapolated to 1 year. Inpatient utilization and costs for T2DM
were reported for the past year. Indirect costs resulting from DM-related produc-
tivity loss due to absenteeism were estimated among employed patients using the
average daily wage of urban employees in Tianjin. All costs were reported in 2011
US dollar using the exchange rate of 6.47 Chinese Yuan to 1 USD. RESULTS: A total
of 279 patients (253 outpatients and 26 inpatients) were included with 50.9% fe-
male, mean age of 60.7 years and mean disease duration of 10.4 years. The mean
annual directmedical costswere $4521: 76.3%were covered by payers and 23.7% by
patients. Outpatient and inpatient costs were $2886 and $1411, accounting for
63.8% and 31.2% of direct medical costs, respectively. The rest were attributed to
medications purchased from retail pharmacies and self-glucose monitoring costs.
Mean annual direct non-medical costs were $209, including $146 nutrition costs,
$63 transportation and accommodation costs. Mean annual costs associated with
productivity loss were $723 among employed patients (n48). CONCLUSIONS:
T2DM poses substantial economic burden to payers, patients and society. The
majority of total costs are attributed to direct medical costs but indirect costs from
productivity loss are substantial among employed patients.
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OBJECTIVES: To examine the relationship between sustained glycemic control and
health care costs among patients with diabetes with an initial hemoglobin A1c
(HbA1c)9%.METHODS:We conducted a retrospective analysis of administrative
data from patients with diabetes and initial poor HbA1c control enrolled in a large
health plan in Hawai‘i (n1304). We used propensity scores to identify a compara-
ble cohort based on age, gender, type of coverage, diabetes duration, number of
medications, location of residence, comorbidity conditions, and morbidity level.
We examined the relationship between reduced HbA1c values and costs in the
same year as well as the impact of achieving sustained HbA1c control (at 7%) for
three years on changes in health care costs using generalized linear models.
RESULTS: In cross-sectional comparisons, the average annual direct medical costs
for patients with a HbA1c less than 7% was $14,821 compared to $12,108 for the
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